Nectome has created a new method for whole-body, whole-brain, human end-of-life preservation for the purpose of future revival. Our protocol is capable of preserving every synapse and every cell in the body with enough detail that current neuroscience says long-term memories are preserved.
Nectome is a Y Combinator company in the Winter 2018 batch. Its directory entry describes it as: Human whole body end-of-life preservation for later revival. The founder listed is Aurelia Song (Founder/CEO) (Y Combinator directory entry, November 2, 2017).
Sell to companies like Nectome? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2017-11-02 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Nectome.
Free to see. No signup.
More on Nectome and the records around it.
Same batch, Healthcare first.
Get an email when Nectome changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Nectome raises, hires or launches. No email unless you switch it on.
Watch Nectome →Get the full cited report on Nectome
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Nectome: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Nectome has created a new method for whole-body, whole-brain, human end-of-life preservation for the purpose of future revival. Our protocol is capable of preserving every synapse and every cell in the body with enough detail that current neuroscience says long-term memories are preserved. It's compatible with traditional funerals at room temperature and stable for hundreds of years at cold temperatures.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Nectome: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nectome covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist NectomeYou get an alert in MentionFox the next time this company shows up.
If you're behind Nectome: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Nectome. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-nectome